Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAP)

Historical Holders from Q2 2015 to Q1 2025

Symbol
ADAP on Nasdaq
CUSIP
00653A107
Type / Class
Equity / Ordinary Shares, par value GBP 0.001 per share
Shares outstanding
1.53B
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
124M
Holdings value
$67M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
77
Number of buys
26
Number of sells
-35
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAP)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Two Seas Capital LP 5.8% $52.5M 89M Two Seas Capital LP Dec 31, 2024
BAILLIE GIFFORD & CO 4.6% $41.8M 70.9M BAILLIE GIFFORD & CO Dec 31, 2024
Long Focus Capital Management, LLC 8% $12.1M 20.5M LONG FOCUS CAPITAL MANAGEMENT, LLC Dec 31, 2024

Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAP)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 282K $55.5K -$17.4K $0.20 9
2024 Q4 124M $67M -$30.5M $0.54 77
2024 Q3 152M $144M -$2.31M $0.95 80
2024 Q2 154M $150M -$8.88M $0.97 75
2024 Q1 162M $256M +$33.1M $1.58 77
2023 Q4 144M $114M -$3.68M $0.79 75
2023 Q3 148M $116M +$2.66M $0.78 76
2023 Q2 145M $134M +$26.6M $0.93 83
2023 Q1 116M $126M +$2.11M $1.09 62
2022 Q4 114M $166M +$542K $1.46 63
2022 Q3 114M $122M -$1.6M $1.08 57
2022 Q2 115M $195M +$7.48M $1.70 68
2022 Q1 109M $224M -$22.1M $2.06 71
2021 Q4 113M $426M -$9.03M $3.75 78
2021 Q3 112M $577M +$3.02M $5.17 90
2021 Q2 112M $476M -$26.2M $4.26 80
2021 Q1 117M $624M -$3.88M $5.31 81
2020 Q4 118M $637M -$92.1M $5.39 82
2020 Q3 130M $1.03B +$4.54M $7.98 73
2020 Q2 128M $1.28B +$369M $10.01 74
2020 Q1 93.8M $255M +$79.5M $2.72 43
2019 Q4 64.9M $77.8M -$4.19M $1.20 33
2019 Q3 68.1M $103M -$1.4M $1.51 40
2019 Q2 68.2M $274M -$5.12M $4.02 52
2019 Q1 69.1M $297M -$2.78M $4.30 61
2018 Q4 69.1M $397M -$2.95M $5.75 72
2018 Q3 65.5M $888M +$132M $13.56 89
2018 Q2 55.9M $663M -$2.4M $11.87 86
2018 Q1 56.2M $631M +$52.1M $11.23 74
2017 Q4 51.3M $342M +$1.99M $6.68 66
2017 Q3 50.8M $416M +$29.1M $8.19 63
2017 Q2 48.1M $216M +$37.7M $4.49 51
2017 Q1 39.8M $218M +$54.9M $5.51 48
2016 Q4 29.8M $121M -$7.13M $4.05 37
2016 Q3 30.9M $218M -$7.77M $7.05 45
2016 Q2 31.9M $260M -$1.11M $8.15 45
2016 Q1 32M $260M +$87.4M $8.13 47
2015 Q4 20.6M $249M +$83.8M $12.06 47
2015 Q3 13.8M $165M -$63.3M $11.97 40
2015 Q2 19.2M $352M +$343M $18.33 44